It’s difficult to discuss the genetic modification of animal models without CRISPR entering the conversation. While technologies like CRISPR/Cas9 have extended the boundaries of what is feasible for model development — increasing the speed and efficiency with which genetic modification can be accomplished, while reducing costs — the excitement and promise associated with CRISPR can create the misperception that it is always the best tool in the toolbox. This misperception can cause confusion, concern, or frustration for researchers who need a genetic modification for which CRISPR may not be the best approach.
The advent of CRISPR as a gene editing tool continues to revolutionize drug discovery and development.
The routine application of human pluripotent stem cells and their derivatives in regenerative medicine and innovative drug discovery will require the constant supply of high cell numbers in consistent, high quality.
This application note details the suitability of Eppendorf BioBLU 0.3c Single-Use Vessels controlled by a DASbox Mini Bioreactor System for the expansion of human bone marrow-derived mesenchymal stem cells on microcarriers.
A look at some drug discovery challenges in details and what solutions could lead to better science and faster insights to action.
The coming years will be an exciting era in genetic research as we discover new biological mechanisms and functions for noncoding RNAs. Our improved understanding of this class of genes should provide insight into novel treatments for cancers.
By delivering significantly more data than traditional Sanger-based sequencing methods, NGS opens a range of possibilities for the analysis of diverse DNA and RNA populations.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective treatment for patients with high risk and relapsed hematologic malignancies. When donor T cells recognize the host as foreign, they induce an immune response against the host and may cause life-threatening graft-versus-host disease (GvHD), a major complication of allo-HSCT.
The biological properties of IgM antibodies make them very effective vehicles for in vitro diagnostics and therapeutics. But, purification of IgM antibodies is more difficult than that for the more common IgG antibodies.
Despite their potential to increase the efficiency healthcare, autologous cell therapy treatments present significant challenges to most companies when it comes to development and manufacturing.
